एअरटेलने एअरटेल अ‍ॅड्ससह (ADS) एड्वर्टाइजिंग टेक्नोलॉजीच्या उद्योगात पाऊल टाकले

-

 एअरटेलने एअरटेल अ‍ॅड्ससह (ADS) एड्वर्टाइजिंग टेक्नोलॉजीच्या उद्योगात पाऊल टाकले


मुंबई 25 फेब्रुवारी 2021:-भारती एअरटेल ("एअरटेल"), भारतातील आघाडीच्या संप्रेषण सोल्यूशन्स प्रदाताने, एअरटेल अ‍ॅड्स (ADS) लाँच करुन एड्वर्टाइजिंग व्यवसायात प्रवेश केला आहे. एअरटेल अ‍ॅड्स एक शक्तिशाली ब्रांड एंगेजमेंट सॉल्‍यूशन आहे.एअरटेल अ‍ॅड्स (जाहिरात) सर्व आकाराच्या ब्रॅण्डना भारतातील चांगल्या ग्राहकांच्या सर्वात मोठ्या गटासाठी एकमत-आधारित आणि प्रायव्हसी-सेफ मोहीम तयार करण्याची परवानगी देते.

भारतात वेगवेगळ्या व्यवसायांमध्ये तसेच मोबाइल, डीटीएच आणि घरांमध्ये 320 मिलियनहून अधिक एअरटेलचे ग्राहक आहेत. एअरटेल मोबाइल ग्राहकांचा सर्वाधिक मासिक डेटा वापर आहे आणि तो 16.8 जीबी आहे आणि सर्वाधिक मासिक एआरपीयू 166 रुपये आहे. एअरटेलची वेगाने वाढणारी डीटीएच आणि होम्स नेटवर्क देशभरातील प्रीमियम कुटुंबांना सेवा देते.

एअरटेलच्या सखोल डेटा विज्ञान क्षमतेचा वापर करून,

Comments

Post a Comment

Popular posts from this blog

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

-
  Indegene acquires Trilogy Writing & Consulting GmbH,  a medical writing consultancy   India, March 27, 2024:  Indegene, a  digital-first, life sciences commercialization company , announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.   Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output. Trilogy has a proven track record of more than 22 years of providing medical writing services to the biopharmaceutica
Read more

TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India

-
Image
TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India Mumbai, 09 June 2023 : The 16th Edition of TiEcon Mumbai, organised by TiE Mumbai at Jio Convention Centre, BKC culminated on an enthusiastic note with a call to build an Anti-Fragile and Sustainable India. It kick-started with marquee speakers focusing on ways to accelerate growth, drive more intelligent engagement, make conscious choices and methods to empower sustainable business building ideas. Speaking at the summit, Ranu Vohra, President- TiE Mumbai said, “It was great to see the energy of the startup eco system at work at TiECon 2023. There were lively debates on Mumbai’s roadmap to becoming the startup hub, Gen AI and its role in India and the opportunities, thus created. The session on funding availability held out promise that as the startups become “anti-fragile” and focus on unit economics and profitability we should see a renewed incre
Read more

REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24

-
REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24   REC RECORDS ITS HIGHEST EVER QUARTERLY PROFIT AT ₹3,773 CRORE Mumbai/New Delhi, November 01, 2023: REC limited, a ‘Maharatna’ company under the administrative control of the Ministry of Power, Government of India, and registered with RBI as Non-Banking Finance Company (NBFC), Public Financial Institution (PFI) and Infrastructure Financing Company (IFC), has today reported its unaudited financial results (Standalone) for the 2nd Quarter and Half Year ended 30th September 2023. Key highlights are as under:  Operational and Financial Highlights –Q2 FY24 vs Q2 FY23 (Standalone) • Sanctions: ₹ 1,04,366 crore vs. ₹ 84,889 crore, up 23%, Renewable sector constitutes for 24% • Disbursements: ₹ 41,598 crore vs. ₹ 17,827 crore, up 133% • Interest Income on Loan Assets: ₹ 11,213 crore vs. ₹ 9,534 crore, up 18% • Net Profit: ₹ 3,773 crore vs. ₹ 2,728 crore, up 38% • Total Comprehensive Income: ₹ 4,188 crore vs. ₹ 1,915 crore, up 1
Read more